innat
nonspecif
resist
mechan
import
barrier
pathogen
particularli
delay
viru
multipl
onset
infect
innat
defens
mechan
includ
seri
mechan
barrier
preexist
inhibitori
molecul
cellular
respons
antimicrobi
activ
antivir
activ
innat
inhibitor
resid
varieti
partli
character
substanc
review
present
innat
antivir
inhibitor
cell
cultur
urin
serum
gastrointestin
tract
nervou
system
tissu
crustacean
saliva
medic
adapt
innat
antivir
defens
mechan
may
use
prevent
treatment
viral
infect
innat
nonspecif
resist
mechan
import
barrier
pathogen
particularli
delay
viru
multipl
onset
infect
prior
develop
specif
immun
respons
dianzani
baron
reactiv
nonspecif
defens
eg
interferon
cytokin
activ
cell
includ
innat
sinc
produc
respons
infect
baron
innat
defens
includ
seri
mechan
barrier
preexist
molecul
cellular
respons
antimicrobi
activ
prior
recognit
nonspecif
defens
scientist
believ
viral
infect
occur
nonimmun
host
believ
bodi
specif
immun
respons
antibodi
immun
cell
weresufficienttoovercometheinvadingvirus
start
day
baron
howev
recognit
earlier
host
defens
exist
hint
key
find
specif
immun
respons
began
sever
day
viru
multipl
brought
control
baron
fig
earli
defens
determin
nonspecif
defens
innat
reactiv
subsequ
studi
confirm
viral
infect
initi
limit
earli
nonspecif
defens
restrict
initi
viru
multipl
manag
level
initi
recoveri
recoveri
complet
combin
earli
nonspecif
defens
subsequ
virusspecif
immun
defens
earli
nonspecif
defens
enabl
host
cope
peak
accumul
virus
present
initi
infect
dose
could
lethal
although
nonspecif
immun
defens
oper
togeth
control
viral
infect
review
consid
mainli
innat
nonspecif
inhibitori
substanc
role
innat
inhibitor
host
defens
suggest
presenc
vivo
signific
antivir
activ
titer
tissu
cultur
direct
correl
degre
virul
virus
degre
resist
certain
inhibitor
correl
made
studi
serum
mucu
inhibitor
influenza
virus
experiment
infect
kriznova
rathova
addit
presenc
inhibitor
vivo
may
explain
rel
high
dose
viru
requir
initi
infect
vivo
compar
low
dose
need
cell
cultur
normal
bodi
fluid
tissu
report
possess
inhibitori
activ
discret
virus
individu
viru
group
broad
spectrum
virus
karzon
kriznova
rathova
kitamura
et
al
shortridg
ho
welsh
et
al
thiri
et
al
suribaldi
et
al
gerna
et
al
singh
baron
sinc
antivir
activ
singl
small
group
virus
poorli
character
enough
inform
fulli
understand
role
host
defens
mechan
recent
molecul
possess
broad
antivir
activ
bodi
better
character
also
may
consid
potenti
effect
defens
viral
infect
focu
review
mainli
properti
broadli
antivir
innat
substanc
use
background
literatur
narrowli
act
inhibitor
throughout
review
refer
antivir
titer
activ
unitsml
uml
one
unitml
antivir
activ
defin
reciproc
highest
dilut
inhibitor
prepar
show
reduct
plaqu
compar
medium
control
kind
assay
u
antivir
activ
mean
sampl
dilut
still
reduc
plaqu
form
unit
virus
comparison
medium
control
cytotox
exclud
mediat
viru
inhibit
laboratori
control
experi
measur
cell
kill
trypan
blue
presenc
inhibitor
also
experi
measur
cell
prolifer
presenc
inhibitor
broadli
activ
inhibitor
virus
vaccinia
polio
vesicular
stomat
found
cultur
fluid
sever
type
normal
human
mous
cell
cultur
viru
plaqueinhibit
activ
appear
cultur
fluid
within
hour
incub
cultur
fresh
medium
peak
inhibitori
activ
occur
within
h
blockad
cellular
ribonucl
acid
protein
synthesi
decreas
appear
inhibitor
inhibit
viru
requir
simultan
presenc
inhibitor
viru
cell
suggest
revers
natur
inhibit
hugh
et
al
degre
inhibitori
activ
depend
anim
speci
origin
inhibitor
cell
type
use
assay
viru
type
use
challeng
cell
speci
barrier
inhibitori
action
found
strong
inhibit
multicycl
yield
vesicular
stomat
viru
sindbi
viru
caus
even
low
dose
inhibitor
character
cvi
respect
molecular
size
stabil
heat
number
chemic
reagent
enzym
indic
antivir
activ
cvi
associ
larg
molecul
approxim
million
da
b
stabl
c
resist
action
rnase
dnase
sulfhydr
reagent
protein
denatur
extract
organ
solvent
sullivan
et
al
characterist
specif
cvi
similar
inhibitor
occur
certain
tissu
extract
bodi
fluid
describ
later
broad
antivir
activ
detect
urin
screen
physiolog
bodi
fluid
presenc
viral
inhibitor
coppenhav
et
al
kumar
et
al
moder
level
uml
antivaccinia
activ
consist
found
steril
filter
urin
normal
donor
baron
et
al
b
similar
amount
antivir
activ
seen
vesicular
stomat
herp
simplex
virus
activ
moieti
exhibit
mark
ph
heat
stabil
studi
present
indic
activ
attribut
ammonium
content
urin
baron
et
al
b
ammonium
salt
known
exert
fairli
broad
antivir
activ
partli
accumul
lysosom
reduc
acid
local
environ
therebi
inhibit
activ
lysosom
enzym
impair
uncoat
process
viru
infect
marsh
heleniu
antivir
activ
urin
account
ammonium
ion
concentr
basi
conclus
twofold
first
physic
characterist
biolog
mechan
urin
inhibitor
similar
authent
nh
second
quantiti
ammonium
salt
normal
present
urin
suffici
explain
level
antivir
activ
physiolog
fluid
ammonium
ion
concentr
bodi
fluid
much
lower
urin
content
nh
gener
inhibit
virus
tietz
addit
ammonium
salt
distinct
previous
report
antivir
mucoprotein
urin
tamm
horsfal
also
determin
simpl
inorgan
amin
suppress
plaqu
format
herp
simplex
type
viru
semliki
forest
viru
respiratori
synciti
viru
rhinoviru
influenza
viru
similar
result
report
ammonium
chlorid
lysomotrop
amin
investig
jensen
et
al
banfield
kisch
norkin
einck
heleniu
et
al
coomb
et
al
although
ammonium
ion
significantli
inhibit
sever
type
virus
breadth
antivir
activ
somewhat
less
inhibitor
found
plasma
gastrointestin
tract
nervou
system
describ
later
natur
viral
infect
viru
shed
urinari
tract
known
less
respiratori
gastrointestin
tract
utz
one
factor
could
explain
decreas
viru
infect
urinari
tract
may
content
ammonium
ion
urin
human
blood
plasma
report
earli
possess
nonspecif
antivir
activ
activ
report
due
sever
preexist
natur
occur
molecul
either
activ
individu
famili
virus
molecul
howev
adequ
studi
reveal
molecular
structur
mechan
action
presum
low
titer
therefor
possibl
role
viremia
partli
understood
recent
two
natur
occur
nonspecif
broadspectrum
antivir
agent
utib
highdens
lipoprotein
hdl
describ
singh
et
al
singh
et
al
activ
dna
envelop
nonenvelop
rna
virus
one
utib
possess
substanti
antivir
activ
uml
serum
comparison
hdl
activ
uml
sinc
preexist
antivir
molecul
serum
appear
circul
defens
mechan
avail
onset
viral
infect
may
signific
restrict
viremia
background
narrowli
act
antivir
activ
report
resid
varieti
uncharacter
partli
character
substanc
inhibitor
distinguish
antibodi
interferon
complement
mani
innat
antivir
substanc
gener
report
act
singl
viru
coronaviru
newcastl
diseas
viru
variola
viru
sendai
viru
vesicular
stomat
viru
karzon
kitamura
et
al
thiri
et
al
suribaldi
et
al
gerna
et
al
activ
individu
viru
famili
includ
myxovirus
togavirus
retrovirus
kriznova
rathova
shortridg
ho
welsh
et
al
mechan
action
viral
inhibitor
known
vari
act
irrevers
neutral
infect
case
coronaviru
sendai
viru
inhibitor
karzon
kitamura
et
al
suribaldi
et
al
gerna
et
al
myxoand
togaviru
inhibitor
appear
prevent
hemaglutin
infect
kriznova
rathova
shortridg
ho
inhibitor
vesicular
stomat
viru
act
penetr
viral
envelop
inactiv
viral
rna
thiri
et
al
retroviru
inhibitor
work
via
complement
mediat
lysi
viral
infect
cell
welsh
et
al
four
broadspectrum
viral
inhibitor
report
human
serum
interferon
tnf
occur
respons
infect
inflamm
cancer
sambhi
et
al
czarniecki
wallac
et
al
two
constitut
abovement
utib
highdens
lipoprotein
hdl
baron
et
al
b
singh
et
al
singh
et
al
broad
antivir
activ
utib
shown
tabl
heparin
may
use
medic
prevent
clot
narrow
antivir
activ
deserv
mention
potent
activ
nahmia
kibrick
baba
et
al
rider
consid
properti
constitut
broadli
activ
inhibitor
ie
utib
hdl
determin
enzymat
inactiv
utib
glycoprotein
molecular
weight
approxim
da
base
hplc
size
exclus
chromatographi
fig
antivir
activ
plaqu
inhibitori
unitsml
stabl
ph
min
mild
oxid
sodium
period
naio
glycolysi
mixtur
glycosidas
destroy
antivir
activ
proteinas
digest
degrad
inhibitor
small
product
b
da
retain
broad
antivir
activ
activ
small
compon
increas
heat
stabil
min
still
inactiv
glycosidas
thu
antivir
activ
appear
resid
mainli
separ
oligosaccharid
moieti
glycoprotein
utib
singh
et
al
human
serum
hdl
lipoprotein
kda
occur
serum
rang
mgdl
antivir
activ
serum
four
viru
plaqueinhibitori
unit
per
ml
antivir
activ
seem
resid
protein
compon
apolipoprotein
apolipoprotein
report
inhibit
hiv
hdl
also
broadli
activ
dna
envelop
nonenvelop
virus
thu
main
broadspectrum
viral
inhibitor
serum
utib
lesser
degre
hdl
singh
et
al
preincub
viru
utib
hdl
result
reduct
infect
indic
irrevers
neutral
viral
infect
similarli
preincub
cell
hdl
utib
unlik
interferon
induc
antivir
state
cell
inhibit
experi
reveal
utib
inhibit
viru
prevent
viru
attach
cell
membran
physiolog
inert
viru
replic
proceed
beyond
initi
attach
target
cell
compar
titer
therefor
impli
antivir
substanc
inhibit
attach
viru
target
cell
significantli
higher
titer
impli
inhibitor
act
postattach
stage
type
experi
show
hdl
unlik
utib
act
virus
postattach
stage
investig
mechan
viral
inhibit
hdl
indic
hdl
inhibit
earli
stage
multipl
cycl
h
initi
infect
like
prevent
penetr
cell
surfac
viru
singh
et
al
possibl
defens
role
narrowli
activ
serum
inhibitor
review
kriznova
rathova
mechan
action
inhibitor
competit
inhibit
viru
attach
cell
neutral
viral
infect
mechan
unlik
classic
antibodi
variou
approach
undertaken
elucid
possibl
role
serum
inhibitor
natur
resist
group
three
categori
first
categori
effort
made
find
correl
suscept
experiment
anim
particular
viru
natur
inhibitori
activ
sera
bang
et
al
smorodintsev
smorodintsev
correl
show
resist
experiment
anim
sever
strain
influenza
viru
correl
presenc
innat
serum
inhibitor
viral
strain
second
categori
effort
made
measur
effect
suppress
delet
serum
inhibitor
suscept
experiment
anim
viru
infect
sever
experi
shown
mice
hamster
fed
ethionin
ethyl
analogu
methoinin
appreci
reduc
inhibitori
activ
serum
influenza
newcastl
diseas
virus
compar
untreat
control
ethioninetr
hamster
suscept
influenza
viru
indic
higher
titer
viru
lung
borecki
et
al
borecki
et
al
observ
point
relationship
vivo
level
serum
inhibitor
influenza
viru
multipl
thu
support
defens
role
narrowli
activ
nonspecif
viral
inhibitor
third
categori
assess
effect
administ
inhibitor
differ
time
viral
infect
experiment
anim
treat
inhibitor
prepar
either
immedi
viru
inocul
use
gamma
serum
inhibitor
multipl
inhibitorsensit
strain
influenza
viru
mous
lung
inhibit
effect
seen
inhibitor
administ
time
viru
time
penetr
suscept
cell
davoli
bartolomeicorsi
cohen
casazza
et
al
link
et
al
link
et
al
thu
gamma
inhibitor
given
intranas
h
postinfect
later
protect
howev
high
dose
inhibitor
given
ip
even
longer
interv
infect
show
appreci
protect
effect
casazza
et
al
appear
overal
gamma
inhibitor
function
defens
mechan
certain
condit
consid
properti
broadli
activ
inhibitor
associ
murin
bovin
gastrointestin
gi
tract
singh
baron
includ
size
structur
activ
chemic
moieti
mechan
action
consid
elsewher
review
broadli
activ
viral
inhibitor
sever
bodi
tissu
fluid
gi
inhibitor
distinct
inhibitor
determin
properti
mechan
antivir
action
describ
studi
human
yet
done
gi
inhibitori
prepar
studi
commerci
porcin
mucos
extract
b
pharmaceut
neuramid
c
mous
intestin
inhibitor
elut
lumen
gi
tissu
porcin
mucos
prepar
nation
formulari
xii
specif
obtain
american
laboratori
inc
omaha
ne
neuramid
partial
purifi
extract
gastric
mucosa
prepar
treat
viral
infect
human
antonelli
et
al
obtain
difacoop
milan
itali
mous
intestin
inhibitor
prepar
made
either
lumin
fluid
eluat
prerins
minc
intestin
icr
femal
mice
singh
baron
intestin
sampl
test
varieti
size
exclus
column
antivir
activ
consist
emerg
column
volum
support
indic
activ
moieti
small
size
synchropak
gpc
peptid
hplc
column
possibl
resolv
small
peptid
neuramid
porcin
mucos
mous
intestin
inhibitor
emerg
appar
molecular
size
b
da
consist
result
dialysi
experi
antivir
activ
retain
da
mwco
membran
base
gpc
peptid
column
result
tent
molecular
weight
da
assign
antivir
moieti
prepar
antivir
activ
three
gastrointestin
inhibitor
prepar
broad
five
viru
type
inhibit
titer
inhibitor
substanti
rang
uml
broad
antivir
activ
confirm
use
partli
purifi
fraction
thu
three
gastrointestin
extract
contain
signific
titer
broadli
antivir
substanc
determin
structur
composit
requir
antivir
activ
extract
treat
degrad
protein
break
carbohydr
linkag
oxid
carbohydr
extract
lipid
residu
antivir
activ
measur
treatment
neuramid
porcin
mucos
mous
intestin
prepar
either
proteinas
k
carbohydras
sodium
period
extract
lipid
solvent
butanol
ethyl
ether
affect
antivir
activ
sinc
carbohydras
degrad
possibl
sugar
linkag
inhibitor
also
treat
naio
gener
oxid
agent
without
inactiv
antivir
activ
find
intestin
prepar
suggest
ordinari
protein
carbohydr
lipid
moieti
may
requir
antivir
activ
gi
inhibitor
determin
whether
intestin
prepar
inactiv
virus
directli
virus
pretreat
inhibitor
assay
residu
infect
pretreat
sindbi
viru
vesicular
stomat
viru
mengoviru
neuramid
porcin
mucos
extract
mous
intestin
inhibitor
reduc
infect
indic
inhibitor
bind
irrevers
virion
perman
neutral
infect
determin
whether
inhibitor
act
attach
later
replic
cycl
inhibitori
titer
compar
titer
neuramid
porcin
mucos
inhibitor
three
virus
significantli
higher
indic
neuramid
porcin
mucos
inhibitor
may
act
block
viral
replic
postattach
stage
mous
intestin
inhibitor
hand
activ
therefor
inhibit
viru
replic
prevent
attach
virion
target
cell
possibl
mechan
action
must
eventu
confirm
use
fulli
purifi
inhibitor
determin
cell
acquir
resist
viru
infect
pretreat
inhibitor
cell
incub
inhibitor
prepar
mous
intestin
neuramid
porcin
mucosa
h
wash
viru
challeng
pretreat
cell
exhibit
resist
subsequ
infect
indic
inhibitor
induc
durabl
antivir
state
target
cell
resist
degrad
gi
inhibitor
could
signific
vivo
sinc
remain
activ
gi
tract
inhibitor
must
resist
action
variou
lipolyt
proteolyt
glycolyt
activ
digest
process
enzymeresist
peptid
carbohydr
report
previous
wita
et
al
alper
zijlstra
et
al
day
et
al
podolski
shen
xu
thu
structur
gi
inhibitor
remain
undetermin
consist
possibl
defens
role
gi
tract
inhibitor
natur
high
titer
broad
antivir
activ
locat
gi
tract
lumen
definit
assign
defens
role
futur
studi
show
administr
inhibitor
protect
vivo
b
delet
inhibitor
enhanc
infect
bloodbrain
barrier
larg
exclud
bodi
host
defens
includ
system
antibodi
immun
cell
cytokin
central
nervou
system
cn
baron
cathala
baron
griffin
innat
antivir
molecul
alreadi
within
brain
may
candid
defens
cn
infect
thu
nervou
system
tissu
extract
studi
abil
inhibit
viru
infect
baron
cathala
baron
griffin
singh
et
al
singh
et
al
baron
et
al
ns
inhibitor
lamb
brain
tissu
exhibit
broad
antivir
activ
dna
virus
envelop
nonenvelop
rna
virus
singh
et
al
baron
et
al
human
bovin
ovin
porcin
lapin
murin
piscin
brain
possess
similar
level
antivir
activ
human
ns
inhibitor
present
brain
spinal
cord
white
gray
matter
sciatic
nerv
cerebrospin
fluid
furthermor
ns
inhibitor
diffus
extracellularli
prerins
brain
tissu
vitro
antivir
activ
due
cell
toxic
differ
vero
cer
cell
growth
h
detect
absenc
presenc
u
inhibitor
furthermor
transferrin
lowdens
lipoprotein
use
nonspecif
protein
control
antivir
use
sucrosedens
gradient
centrifug
sullivan
et
al
singh
et
al
high
level
antivir
activ
detect
sucros
band
fig
result
indic
antivir
factor
brain
extract
least
kda
lipid
extract
reduc
size
antivir
compon
without
inactiv
inhibitori
activ
antivir
activ
lipidextract
materi
mous
lamb
brain
reduc
molecular
weight
less
da
equival
size
result
obtain
use
superdex
superdex
fplc
size
column
also
analyz
size
antivir
materi
releas
butanoleth
extract
use
gpc
peptid
hplc
column
antivir
activ
emerg
near
lower
limit
resolv
power
column
calcul
molecular
weight
da
appear
butanoleth
extract
high
molecular
weight
antivir
materi
brain
tissu
releas
low
molecular
weight
moieti
da
possess
broad
antivir
activ
fig
sediment
rate
viru
inhibitor
lamb
brain
tissu
discontinu
sucros
gradient
sucros
solut
pb
mm
use
form
step
gradient
equival
volum
brain
inhibitor
prepar
ml
sucros
mix
layer
discontinu
gradient
centrifug
revmin
rotor
min
collect
fraction
examin
antivir
activ
sindbi
viru
extens
dialysi
reprint
permiss
re
thermost
studi
show
nativ
brain
tissu
antivir
activ
stabl
least
h
inhibitori
activ
also
stabl
follow
treatment
dtt
nbutanol
ethyl
ether
viral
inhibitori
activ
crude
brain
extract
abolish
proteolysi
enzymat
glycolysi
period
oxid
impli
nativ
inhibitor
molecul
contain
protein
carbohydr
structur
necessari
maintain
antivir
activ
howev
lipidextract
small
inhibitor
molecul
resist
proteolysi
glycolysi
heat
resist
stabl
min
nativ
inhibitor
taken
togeth
evid
indic
natur
inhibitor
moieti
brain
compos
lipid
protein
carbohydr
disrupt
structur
proteolysi
glycolysi
inactiv
inhibitori
activ
pretreat
virus
inhibitor
h
affect
infect
indic
inhibitor
neither
bound
irrevers
virion
perman
neutral
infect
determin
whether
inhibitor
act
attach
later
replic
cycl
inhibitori
titer
compar
addit
experi
viru
yield
determin
time
addit
inhibitor
prepar
cell
monolay
taken
togeth
result
indic
inhibit
attach
stage
viru
multipl
pretreat
cell
induc
resist
subsequ
infect
virus
indic
unlik
ifn
inhibitori
materi
induc
durabl
antivir
state
target
cell
possibl
regul
ns
antivir
activ
level
neural
tissu
respons
ongo
infect
assess
use
encephalit
flaviviru
infect
mice
inhibitor
titer
determin
day
infect
encephalit
banzi
viru
singh
et
al
time
chosen
sinc
bzv
detect
mous
brain
day
pi
singh
et
al
chang
inhibitori
titer
seen
throughout
lethal
infect
fig
indic
inhibitor
unlik
ifn
antibodi
specif
induc
decreas
respons
viral
infect
possibl
constitut
antivir
inhibitor
nervou
system
could
affect
pathogenesi
studi
determin
baron
et
al
whether
inhibitor
wide
distribut
human
nervou
system
releas
extracellularli
b
present
effect
concentr
c
protect
vivo
see
distribut
system
found
ns
inhibitor
wide
distribut
human
white
matter
gray
matter
spinal
cord
peripher
sciatic
nerv
tissu
cerebrospin
fluid
exclud
larg
molecul
inhibitori
activ
human
nervou
system
properti
inhibitor
mammalian
brain
singh
et
al
properti
kda
size
complex
structur
lipid
essenti
protein
carbohydr
presum
aggreg
micellar
structur
competit
inhibit
viru
attach
broad
antivir
activ
thu
ns
inhibitor
locat
nervou
system
tissu
infect
virus
importantli
inhibitori
activ
diffus
prewash
minc
brain
extracellular
fluid
extracellular
space
use
mani
virus
spread
thu
inhibitor
appropri
extracellular
neural
compart
interdict
viru
attach
cell
antivir
titer
inhibitor
nervou
system
rang
ug
tissu
comparison
titer
host
defens
antibodi
interferon
measur
type
assay
rang
baron
thu
concentr
ns
inhibitor
appear
suffici
play
defens
role
put
host
defens
protect
vivo
well
vitro
vivo
protect
studi
demonstr
subcutan
administr
ns
inhibitor
alphaviru
picornaviru
result
prolong
surviv
protect
death
find
show
ns
inhibitor
protect
vivo
virus
infect
nervou
system
overal
natur
defens
role
broadli
antivir
ns
inhibitor
suggest
constitut
high
concentr
wide
distribut
tissu
nervou
system
presenc
extracellular
fluid
protect
mice
baron
et
al
fig
level
viru
inhibitor
mous
brain
extract
unchang
enceph
threeweekold
femal
outbr
icr
mice
infect
intraperiton
ld
bzv
brain
harvest
day
postinfect
homogen
viru
inhibitori
level
homogen
titer
sindbi
viru
depict
bar
graph
left
axi
rise
viru
titer
brain
sera
infect
mice
taken
singh
et
al
superimpos
illustr
cours
bzv
infect
viru
load
brain
viru
load
per
ml
serum
reprint
permiss
re
viral
inhibitor
tissu
crustacean
pan
et
al
tissu
extract
invertebr
crustacean
crab
shrimp
crayfish
broadli
antivir
varieti
virus
includ
dna
envelop
nonenvelop
rna
virus
character
inhibitor
indic
molecular
size
main
inhibitor
antivir
activ
inhibitor
prepar
reduc
lipid
extract
butanol
unaffect
treatment
dtt
urea
proteinas
k
carbohydras
inhibitor
prepar
directli
neutral
viru
infect
inhibitor
appear
act
viru
attach
stage
addit
crab
inhibitor
prepar
also
induc
durabl
antivir
state
vero
cell
subsequ
infect
sindbi
vaccinia
virus
due
interferon
nonspecif
broadli
antivir
substanc
present
crustacean
may
host
defens
substanc
may
contribut
surviv
crustacean
despit
continu
exposur
extrem
high
dose
virus
fuhrman
virus
common
biolog
agent
sea
number
ten
billion
per
liter
probabl
infect
mani
speci
fuhrman
viral
infect
common
crustacean
instanc
penaeid
shrimp
infect
least
virus
johnson
et
al
johnson
et
al
blue
crab
infect
natur
experiment
rotaviru
enteroviru
newcastl
diseas
viru
polioviru
mccumber
clem
seidel
et
al
comparison
vertebr
invertebr
produc
specif
antibodi
schapiro
therefor
may
reli
innat
defens
protect
virus
schnapp
et
al
littl
known
possibl
innat
antivir
substanc
invertebr
thu
crustacean
crab
shrimp
crayfish
appropri
invertebr
subject
studi
innat
immun
virus
pan
et
al
inhibitor
extract
crab
broadli
inhibitori
six
type
dna
rna
virus
test
titer
inhibitor
vari
moder
differ
virus
inhibitori
activ
tissu
extract
two
crustacean
shrimp
crawfish
also
found
broadli
activ
virus
titer
compar
crab
inhibitor
prepar
inhibitori
effect
inhibitor
prepar
detect
either
cellfre
hiv
hivinfect
cell
crab
inhibitor
prepar
fraction
sizeexclus
chromatographi
superdex
fplc
column
individu
fraction
test
presenc
antivir
activ
antivir
peak
uml
correspond
molecular
mass
approxim
kda
addit
secondari
peak
rel
low
antivir
activ
uml
found
fraction
correspond
molecular
size
kda
lipid
extract
butanol
significantli
decreas
antivir
activ
residu
aqueou
phase
inhibitor
prepar
lipid
extract
also
result
reduct
size
antivir
substanc
evidenc
filter
residu
antivir
activ
k
mwco
ultrafiltr
membran
filtron
northborough
contrast
neither
insolubl
proteinas
k
cocktail
glycosidas
significantli
inactiv
antivir
activ
inhibitor
prepar
addit
sulfhydryl
reagent
dtt
chaotrop
reagent
urea
use
treat
inhibitor
prepar
loss
antivir
activ
found
thu
inhibitor
resist
mani
chemic
degrad
crab
inhibitor
prepar
irrevers
inactiv
virus
determin
whether
inhibitor
prepar
act
viru
attach
thereaft
antivir
activ
compar
equal
activ
indic
one
action
crab
inhibitor
prevent
viru
attach
target
cell
determin
whether
inhibitor
prepar
also
induc
durabl
antivir
activ
host
cell
inhibitor
prepar
preincub
vero
cell
overnight
wash
viru
challeng
inhibitor
preparationpretr
vero
cell
resist
subsequ
infect
sindbi
vaccinia
virus
indic
crab
inhibitor
prepar
also
induc
durabl
antivir
state
vero
cell
subsequ
infect
sindbi
vaccinia
virus
contrast
vesicular
stomat
viru
inhibit
pretreat
cell
indic
revers
probabl
differ
mechan
inhibit
possibl
two
differ
inhibitor
oral
caviti
uniqu
among
mucos
surfac
defens
barrier
transmiss
hiv
probabl
relat
human
tcell
leukemia
viru
mohor
phillip
bourinbaiar
milman
sharma
bomsel
zacharopoulo
phillip
main
defens
mechan
appear
inactiv
transmit
leukocyt
hypoton
saliva
addit
protect
may
contribut
less
activ
salivari
inhibitor
coppenhav
et
al
fultz
fox
et
al
fox
et
al
archibald
cole
yeh
et
al
bergey
et
al
mcneeli
et
al
crombi
et
al
salivari
defens
appear
explain
rariti
casual
hiv
transmiss
oral
howev
normal
effect
oral
barrier
overcom
solut
semin
fluid
milk
colostrum
mayer
degruttola
lifson
et
al
quatro
et
al
lane
et
al
ryder
et
al
dunn
et
al
keet
et
al
bertolli
et
al
black
berrey
shea
cao
et
al
special
import
medic
applic
salivari
defens
direct
attent
hivinfect
leukocyt
main
mucos
transmit
agent
consequ
anticellular
solut
potent
saliva
hypoton
could
appli
topic
vulner
mucos
site
eg
vagina
rectum
inactiv
infect
leukocyt
semin
fluid
prevent
vagin
rectal
transmiss
studi
candid
topic
anticellular
substanc
reportedli
ineffect
mohor
pauza
et
al
pauza
et
al
done
candid
prevent
includ
disinfect
blood
product
bile
deterg
overthecount
otc
commerci
vagin
product
effect
vitro
otc
product
alreadi
establish
safe
use
fda
standard
hiv
epidem
began
initi
concern
hiv
might
transmit
casual
oral
secret
million
hiv
carrier
kiss
dental
treatment
bite
aerosol
later
becam
clear
casual
transmiss
actual
rare
event
even
infecti
hiv
shed
oral
caviti
bleed
exud
ho
et
al
levi
greenspan
roger
et
al
gooch
et
al
moor
et
al
richman
rickman
yeung
et
al
piazza
et
al
saliva
infect
individu
usual
contain
noninfecti
compon
hiv
includ
viral
dna
indic
saliva
may
caus
breakdown
infect
leukocyt
infect
saliva
vitro
although
carrier
infecti
viru
blood
goto
et
al
barr
et
al
moor
et
al
coppenhav
et
al
qureshi
et
al
melvin
et
al
baron
et
al
comparison
semin
fluid
percentag
patient
shed
hiv
mainli
infect
leukocyt
much
higher
approxim
milman
sharma
vernazza
et
al
zhu
et
al
thu
rariti
casual
oral
transmiss
correl
low
infect
saliva
compar
high
infect
semin
fluid
associ
vagin
transmiss
european
studi
group
johnson
et
al
lazzarin
et
al
european
studi
group
heterosexu
transmiss
hiv
royc
et
al
therefor
import
determin
salivari
mechan
protect
mani
inhibitor
hiv
saliva
coppenhav
et
al
fultz
fox
et
al
fox
et
al
archibald
cole
yeh
et
al
bergey
et
al
mcneeli
et
al
mcneeli
et
al
crombi
et
al
shugar
baron
et
al
import
question
mani
report
salivari
inhibitor
hiv
best
account
saliva
protect
hivinfect
leukocyt
salivari
inhibitor
includ
antibodi
lysozym
peroxidas
complement
cystatin
lactoferrin
defensin
mucin
amylas
statherin
prolinerich
peptid
histatin
rnase
leehuang
et
al
secretori
leukocyt
proteas
inhibitor
coppenhav
et
al
fultz
fox
et
al
fox
et
al
archibald
cole
sun
et
al
yeh
et
al
robinovitch
et
al
bergey
et
al
mcneeli
et
al
mcneeli
et
al
shugar
exist
undiscov
salivari
inhibitor
suggest
known
salivari
inhibitor
inhibit
hiv
suffici
explain
rariti
oral
transmiss
coppenhav
et
al
fultz
fox
et
al
fox
et
al
archibald
cole
sun
et
al
yeh
et
al
robinovitch
et
al
bergey
et
al
mcneeli
et
al
mcneeli
et
al
shugar
new
inhibitor
also
suggest
uniqu
hypoton
sali
fig
saliva
interrupt
multipl
human
immunodefici
viru
hiv
infect
human
mononuclear
leukocyt
p
student
ttest
reprint
permiss
arch
intern
med
va
ie
oneseventh
tonic
normal
interstiti
fluid
benaryeh
et
al
edgar
hypoton
shown
disrupt
crucial
infect
leukocyt
therebi
render
incap
support
viru
multipl
celltocel
transmiss
hiv
fig
specif
inhibit
multipl
hiv
hypoton
saliva
compar
inhibit
macromolecular
inhibitor
saliva
also
reconstitut
isoton
saliva
revers
inhibit
baron
fig
dilut
blood
milk
colostrum
semin
fluid
prevent
saliva
inhibit
hiv
multipl
human
pbl
p
student
ttest
reprint
permiss
j
infect
di
thu
hypoton
disrupt
appear
major
mechan
saliva
kill
transmit
mononuclear
leukocyt
therebi
prevent
attach
mucos
epitheli
cell
product
infecti
hiv
unexplain
howev
paradox
oral
transmiss
hiv
occur
epidemiolog
infect
semin
fluid
mayer
degruttola
lifson
et
al
quatro
et
al
lane
et
al
keet
et
al
berrey
shea
milk
ryder
et
al
dunn
et
al
bertolli
et
al
black
cao
et
al
deposit
oral
despit
presenc
saliva
mechan
carrier
semin
fluid
milk
may
overcom
protect
recipi
saliva
studi
hypothes
reconstitut
salt
hypoton
saliva
oral
deposit
isoton
semin
fluid
milk
colostrum
would
revers
saliva
abil
inactiv
virusinfect
leukocyt
girgi
et
al
kavanagh
mehl
levi
vonesch
et
al
buranasin
et
al
goldman
goldblum
experiment
volum
semin
fluid
milk
colostrum
deposit
mouth
found
contain
suffici
solut
overcom
saliva
normal
hypoton
protect
hivinfect
leukocyt
therebi
appear
explain
paradox
success
oral
transmiss
fluid
fig
conclus
confirm
revers
salivari
protect
ad
salt
saliva
dialysi
cultur
medium
throughout
histori
medicin
effect
antimicrobi
applic
come
understand
adapt
natur
defens
mechan
exampl
natur
separ
host
microb
adapt
sanit
quarantin
host
immun
respons
adapt
vaccin
passiv
immun
microbi
molecul
selfprotect
adapt
antibiot
similar
applic
innat
antivir
defens
overview
tabl
may
result
new
medic
use
antivir
substanc
strategi
